CEO funds Apollomics (Nasdaq: APLM) with $2M zero-interest convertible note

Rhea-AI Filing Summary

Apollomics Inc. entered into a $2,000,000 unsecured Convertible Promissory Note with its Chairman and CEO, Hung-Wen (Howard) Chen, providing short-term bridge financing. The Note carries a 0% interest rate and is intended to supply working capital for clinical development programs and general corporate operations.

The principal will automatically convert into Apollomics equity upon a future equity financing that raises at least $10,000,000, at a conversion price set at 80% of the lowest per-share price paid by new investors. If no such financing occurs before the 18‑month maturity, Mr. Chen may elect to convert based on the 10‑day average closing price. As a related-party transaction, it was reviewed by the independent Audit Committee and approved by the Board, with Mr. Chen abstaining.

Insights

Corporate finance analyst

$2M insider bridge loan gives Apollomics short-term funding but signals reliance on its CEO.

Apollomics obtained a $2,000,000 unsecured, 0% interest convertible note from its Chairman and CEO, Hung-Wen Chen. The structure defers cash interest costs and ties repayment largely to equity issuance, which can help preserve cash during ongoing clinical development.

The note automatically converts at a 20% discount to the lowest price in a future equity round raising at least $10,000,000. If no such round occurs before the 18‑month maturity, Mr. Chen may convert at the prior 10‑day average share price. Governance safeguards include review by the independent Audit Committee and Board approval with Chen abstaining.

Key Figures

Bridge financing amount: $2,000,000 Interest rate: 0% per annum Trigger equity financing size: $10,000,000 +3 more

6 metrics

Bridge financing amount $2,000,000 Principal of unsecured Convertible Promissory Note

Interest rate 0% per annum Interest on the Convertible Promissory Note

Trigger equity financing size $10,000,000 Minimum aggregate gross proceeds for automatic conversion

Conversion discount 20% Discount to lowest per-share price in Next Equity Financing

Maturity 18 months Period from issuance before holder elective conversion feature

Use of proceeds $2,000,000 Working capital and general corporate purposes for clinical operations

Key Terms

Convertible Promissory Note, related-party transaction, equity financing, conversion price, +1 more

5 terms

Convertible Promissory Note financial

"entered into a Convertible Promissory Note (the “Note”) with Mr. Hung-Wen"

A convertible promissory note is a loan a company takes now that can later be turned into shares instead of being repaid in cash. Think of it as lending money with the option to accept ownership in the business down the road; that matters to investors because it affects who gets paid first, how much ownership existing shareholders keep, and the company’s future valuation and cash needs. Terms such as conversion price, interest and maturity determine the financial impact.

related-party transaction financial

"Because Mr. Chen is an executive officer and director of the Company, the issuance of the Note constitutes a related-party transaction."

A related-party transaction is a deal, payment or transfer of value between a company and people or entities closely connected to its managers, directors or major owners—think of a business hiring a company owned by the CEO’s sibling. Investors care because such deals can be biased, overprice goods or hide conflicts of interest, affecting profits and trust; clear disclosure and fair terms help ensure the company is run in shareholders’ best interest.

equity financing financial

"upon the closing of the Company’s next equity financing that raises aggregate gross proceeds of not less than $10,000,000"

Equity financing is when a company raises money by selling ownership pieces (shares) to investors instead of borrowing; think of selling slices of a pie to get cash for the business. It matters to investors because buying shares gives them a claim on future profits and a voice in decisions, while existing owners give up some control and the value of each slice can change as the company grows or falters.

conversion price financial

"the conversion price will be equal to 80% of the lowest per-share purchase price"

The conversion price is the fixed price at which a convertible security, like a bond or preferred stock, can be exchanged for shares of common stock. It acts like a set rate that determines how many shares an investor can receive if they choose to convert their investment. This helps investors understand the value and potential benefits of converting their securities into company shares.

working capital financial

"The Company intends to use the proceeds from the Note for working capital and general corporate purposes"

Working capital is the money a business has available to cover its daily expenses, like paying bills and buying supplies. It’s like the cash in your wallet that helps you handle everyday costs; having enough ensures the business can operate smoothly without running into money shortages.

Form 6-K: How Foreign Companies Report to the SEC →

OMB APPROVAL
OMB Number:		3235-0116
Expires:		December 31, 2026
Estimated average burden
hours per response		8.7

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2026.

Commission File Number 001-41670

Apollomics Inc.

Not Applicable

(Translation of registrant’s name into English)

989 E. Hillsdale Blvd., Suite 220, Foster City, California 94404

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☒ Form 20-F    ☐ Form 40-F

Entry into a Material Definitive Agreement; Related Party Transaction

On March 30, 2026, Apollomics Inc. (the “Company”) entered into a Convertible Promissory Note (the “Note”) with Mr. Hung-Wen (Howard) Chen, the Company’s Chairman and Chief Executive Officer. Pursuant to the Note, Mr. Chen provided an unsecured bridge loan to the Company in the principal amount of $2,000,000.

The Note bears no interest (0% per annum) and is unsecured. The principal amount will automatically convert into equity securities of the Company upon the closing of the Company’s next equity financing that raises aggregate gross proceeds of not less than $10,000,000 (the “Next Equity Financing”). Upon such conversion, the conversion price will be equal to 80% of the lowest per-share purchase price paid by investors in the Next Equity Financing. If the Note is not converted prior to the eighteen-month anniversary of its issuance (the “Maturity Date”), the Holder may elect to convert the Note into Class A ordinary shares of the Company based on the average closing price of the shares for the ten trading days immediately preceding the Maturity Date.

Because Mr. Chen is an executive officer and director of the Company, the issuance of the Note constitutes a related-party transaction. The transaction was reviewed and recommended by the Audit Committee, which consists entirely of independent directors, and was subsequently approved by the Board of Directors, with Mr. Chen abstaining from the vote.

The Company intends to use the proceeds from the Note for working capital and general corporate purposes to support its ongoing clinical operations.

The information contained in this Form 6-K is incorporated by reference into the Company’s registration statements under the Securities Act of 1933, as amended, including its registration statements on Form S-8 (File Nos. 333-272559 and 333-293148) and Form F-3 (File Nos. 333-278430, 333-278431, 333-279549, and 333-294154), and shall be a part thereof, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit No.		Description
10.1		Convertible Promissory Note, dated March 30, 2026, issued by Apollomics Inc. to Hung-Wen Chen
99.1		Press Release dated April 1, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2 of 2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

APOLLOMICS INC.

(Registrant)

Date April 1, 2026

/s/ Peter Lin

(Signature)*

Peter Lin, Chief Financial Officer

* Print the name and title under the signature of the signing officer.

.SEC 1815 (07-22) Potential persons who are to respond to the collection of information contained in this Form are not required to respond unless the Form displays a currently valid OMB control number.

3 of 3

Exhibit 99.1

PRESS RELEASE

Apollomics Inc. Announces $2.0 Million Bridge Financing

FOSTER CITY, Calif., April 1, 2026 (GLOBE NEWSWIRE) – Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced that it has entered into a $2.0 million unsecured Convertible Promissory Note (the “Note”) with Mr. Hung-Wen (Howard) Chen, the Company’s Chairman and Chief Executive Officer, on March 30, 2026.

The $2.0 million in proceeds from the Note are intended to provide the Company with necessary working capital to support clinical development programs and general corporate operations.

The Note is an unsecured obligation of the Company and carries a 0% interest rate. Under the terms of the agreement, the principal amount will automatically convert into equity securities of the Company upon the closing of a subsequent equity financing with aggregate gross proceeds of at least $10.0 million. The conversion price will be calculated at a 20% discount to the lowest per-share price issued to investors in such financing.

The terms of the related-party transaction were reviewed and approved by the Company’s independent Audit Committee and the Board of Directors, with Mr. Chen abstaining from the vote. The transaction followed a comprehensive evaluation of the Company’s financing alternatives and a benchmarking analysis against current market terms for similar bridge financing transactions in the biotechnology sector.

About Apollomics Inc.

Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and over 10 other countries. For more information, please visit www.apollomicsinc.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes statements that constitute “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present or historical fact included in this press release, regarding Apollomics’ strategy, prospects, plans, objectives, including with respect to the anticipated use of proceeds from the Note, the potential conversion

of the Note into equity securities, and the Company’s future financing plans, are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “seek,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words.

These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Apollomics cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of Apollomics. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including: (i) the impact of any current or new government regulations in the United States and China affecting Apollomics’ operations and the continued listing of Apollomics’ securities; (ii) the inability to achieve successful clinical results or to obtain licensing of third-party intellectual property rights for future discovery and development of Apollomics’ oncology projects; (iii) the failure to commercialize product candidates and achieve market acceptance of such product candidates; (iv) the failure to protect Apollomics’ intellectual property; (v) breaches in data security; (vi) the risk that Apollomics may not be able to develop and maintain effective internal controls; (vii) unfavorable changes to the regulatory environment; and (viii) those risks and uncertainties discussed in the Annual Report on Form 20-F for the year ended December 31, 2024 (filed with the SEC on April 3, 2025) under the heading “Risk Factors” and the other documents filed, or to be filed, by Apollomics with the SEC. These SEC filings are available publicly on the SEC’s website at www.sec.gov. Forward-looking statements speak only as of the date made by Apollomics. Apollomics undertakes no obligation to update publicly any of its forward-looking statements to reflect actual results, new information or future events, except to the extent required by applicable law.

Investor Contacts:

Peter Lin, Chief Financial Officer

Apollomics, Inc.

1-650-209-4055

peter.lin@apollomicsinc.com

FAQ

What financing did Apollomics (APLM) announce in this Form 6-K?

Apollomics entered into a $2,000,000 unsecured Convertible Promissory Note with its Chairman and CEO. The 0% interest bridge financing is intended to provide working capital to support clinical development programs and general corporate operations while the company pursues longer-term funding options.

What are the key conversion terms of Apollomics’ $2.0 million note?

The $2.0 million principal will automatically convert into Apollomics equity after a future equity financing that raises at least $10.0 million. The conversion price will be set at a 20% discount to the lowest per-share price paid by investors in that qualifying financing round.

What happens if Apollomics does not complete a $10 million equity financing?

If no qualifying equity financing occurs before the 18‑month maturity date, the note’s holder, Hung-Wen Chen, may elect to convert into Class A ordinary shares. The conversion price would then be based on the average closing price over the ten trading days before the maturity date.

Why is this Apollomics financing considered a related-party transaction?

The transaction is a related-party deal because the lender, Hung-Wen (Howard) Chen, is Apollomics’ Chairman and Chief Executive Officer. To address this, the independent Audit Committee reviewed the terms and the Board of Directors approved the note, with Mr. Chen abstaining from the vote.

How will Apollomics use the $2.0 million in bridge financing proceeds?

Apollomics intends to use the $2.0 million in proceeds for working capital and general corporate purposes. The company specifically notes that the funds will support its ongoing clinical development operations as it advances oncology programs such as its lead candidate vebreltinib.

What governance steps did Apollomics take to approve the CEO’s note financing?

The terms of the convertible note were reviewed and recommended by Apollomics’ independent Audit Committee. The Board of Directors then approved the transaction, and Chairman and CEO Hung-Wen Chen, as the lender, abstained from the Board vote to mitigate conflicts of interest.

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 8.4 KB

Agreements & Contracts

• EX-10.1 EX-10.1 39.3 KB